Matches in Wikidata for { <http://www.wikidata.org/entity/Q107973460> ?p ?o ?g. }
Showing items 1 to 39 of
39
with 100 items per page.
- Q107973460 description "clinical trial" @default.
- Q107973460 description "ensayo clínico" @default.
- Q107973460 description "ensayu clínicu" @default.
- Q107973460 description "klinisch onderzoek" @default.
- Q107973460 description "клінічне випробування" @default.
- Q107973460 description "临床试验" @default.
- Q107973460 name "The Efficacy and Safety of Switching to Flumatinib Versus Dasatinib After Imatinib-related Low-grade Adverse Events in CML-CP Patients" @default.
- Q107973460 name "The Efficacy and Safety of Switching to Flumatinib Versus Dasatinib After Imatinib-related Low-grade Adverse Events in CML-CP Patients" @default.
- Q107973460 type Item @default.
- Q107973460 label "The Efficacy and Safety of Switching to Flumatinib Versus Dasatinib After Imatinib-related Low-grade Adverse Events in CML-CP Patients" @default.
- Q107973460 label "The Efficacy and Safety of Switching to Flumatinib Versus Dasatinib After Imatinib-related Low-grade Adverse Events in CML-CP Patients" @default.
- Q107973460 prefLabel "The Efficacy and Safety of Switching to Flumatinib Versus Dasatinib After Imatinib-related Low-grade Adverse Events in CML-CP Patients" @default.
- Q107973460 prefLabel "The Efficacy and Safety of Switching to Flumatinib Versus Dasatinib After Imatinib-related Low-grade Adverse Events in CML-CP Patients" @default.
- Q107973460 P1050 Q107973460-A651C90A-58A6-4AFC-93F4-EF3A03D2A40F @default.
- Q107973460 P1132 Q107973460-38D393B3-94F1-4A11-9CA1-4F69CD84ACD3 @default.
- Q107973460 P1476 Q107973460-CB9BFFA6-239A-4C72-9646-F230D139CCBF @default.
- Q107973460 P2899 Q107973460-FCBBB892-4DF5-4A70-B42F-6DCCF964E4BF @default.
- Q107973460 P3098 Q107973460-85D82337-44E9-4532-8F0B-7C27996D8FA2 @default.
- Q107973460 P31 Q107973460-324718F4-098D-49E3-A8A2-929678E49AE4 @default.
- Q107973460 P4844 Q107973460-6E2A13B5-9579-418D-A5D7-5E2615928F35 @default.
- Q107973460 P580 Q107973460-FEC6915A-2975-469C-A1EB-CAA066E8B55A @default.
- Q107973460 P582 Q107973460-0A9DFDC2-C3D8-4588-BFA8-3731D8EE9FE8 @default.
- Q107973460 P6099 Q107973460-32A34136-D33A-4149-A336-70A21D8B8233 @default.
- Q107973460 P6153 Q107973460-F158AD80-C1FB-4509-A8A5-68A9D4D9B879 @default.
- Q107973460 P8005 Q107973460-4168D62E-A4C1-4AEF-8312-73007FCFD44E @default.
- Q107973460 P8363 Q107973460-8BC055DA-8FB8-4399-9B94-39A568F04CAA @default.
- Q107973460 P1050 Q29496 @default.
- Q107973460 P1132 "+118" @default.
- Q107973460 P1476 "The Efficacy and Safety of Switching to Flumatinib Versus Dasatinib After Imatinib-related Low-grade Adverse Events in Patients With Chronic Myeloid Leukemia in Chronic Phase: an Randomized Controlled Trial." @default.
- Q107973460 P2899 "+18" @default.
- Q107973460 P3098 "NCT04933526" @default.
- Q107973460 P31 Q30612 @default.
- Q107973460 P4844 Q419940 @default.
- Q107973460 P580 "2021-07-01T00:00:00Z" @default.
- Q107973460 P582 "2023-04-30T00:00:00Z" @default.
- Q107973460 P6099 Q42825046 @default.
- Q107973460 P6153 Q11153071 @default.
- Q107973460 P8005 Q76649614 @default.
- Q107973460 P8363 Q78089383 @default.